Insider Selling: Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Sells 695 Shares of Stock

Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Andrew Spaventa sold 695 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $22.55, for a total value of $15,672.25. Following the completion of the transaction, the chief executive officer now owns 1,537 shares of the company’s stock, valued at $34,659.35. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Andrew Spaventa also recently made the following trade(s):

• On Sunday, September 15th, Andrew Spaventa sold 175 shares of Singular Genomics Systems stock. The shares were sold at an average price of $12.38, for a total value of $2,166.50.

Singular Genomics Systems Stock Performance

Shares of Singular Genomics Systems stock traded down $0.44 on Wednesday, reaching $22.53. 6,307 shares of the company were exchanged, compared to its average volume of 34,714. The company has a current ratio of 8.77, a quick ratio of 8.04 and a debt-to-equity ratio of 0.05. Singular Genomics Systems, Inc. has a one year low of $5.34 and a one year high of $23.41. The company has a 50-day moving average of $14.66 and a 200 day moving average of $11.17.

Singular Genomics Systems (NASDAQ:OMIC) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($6.72) EPS for the quarter, beating analysts’ consensus estimates of ($8.05) by $1.33. The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $0.74 million. Singular Genomics Systems had a negative net margin of 3,237.89% and a negative return on equity of 54.70%.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.